The GHD treatment landscape is evolving with novel formulations and delivery systems enhancing patient care. Leading companies including Novo Nordisk, Pfizer, and Eli Lilly are developing advanced recombinant growth hormones and long-acting analogs that improve treatment efficacy and convenience. Refined diagnostic criteria and monitoring protocols are enabling more personalized management approaches for both pediatric and adult patients. View Market Analysis: https://shorturl.at/RdpJB